Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AVT03

Monoclonal antibody · Antagonist of RANKL (TNFSF11) · developed by Alvotech Swiss

Phase 3 Most advanced trial (none active)
ALVO Developer
1 Registered trials

What is AVT03?

AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody that binds RANKL, a protein that drives osteoclast formation and activity. It is given as a subcutaneous injection and is studied in postmenopausal osteoporosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
RANKL (TNFSF11)
Mechanism
Antagonist of RANKL (TNFSF11)
Therapy area
Musculoskeletal
Developer
Alvotech Swiss AG (ALVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05395091 Phase 3 Osteoporosis, Postmenopausal Completed ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoporosis, Postmenopausal

Other drugs acting on TNFSF11

More from Alvotech Swiss

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALVO page.

Follow ALVO, the company behind AVT03

See ALVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.